Randomized trials of fludarabine or alemtuzumab versus alkylating agent-based regimens as initial treatment for chronic lymphocytic leukemia (CLL).
| Study . | Agent . | No. Pts. . | % CR . | % OR . | RD . | OS (mo) . |
|---|---|---|---|---|---|---|
| Abbreviations: GCLLSG, German CLL Study Group; Pts, patients; CR, complete remission; OR, overall response; RD, remission duration; OS, overall survival; mo, months; NR, not reached; TTP, time-to-progression; NA, not available; UK LRF, UK Leukemia Research Fund | ||||||
| Leporrier et al9 | Fludarabine vs | 341 | 40 | 71 | 32 mo (TTP) | 69 |
| CAP vs | 240 | 15 | 58 | 28 mo (TTP) | 70 | |
| CHOP | 357 | 30 | 72 | 30 mo (TTP) | 67 | |
| Rai et al10 | Fludarabine + | |||||
| Chlorambucil vs | 123 | 20 | 61 | NR | 55 | |
| Fludarabine vs | 170 | 20 | 63 | 25 mo (TTP) | 66 | |
| Chlorambucil | 181 | 4 | 37 | 14 mo (TTP) | 56 | |
| French Coop. Group8 | Fludarabine vs | 52 | 23 | 71 | NR | 60%@4 yr |
| CAP | 48 | 17 | 60 | 7 | 60%@4 yr | |
| GCLLSG-CLL511 | Fludarabine vs | 46 | 11 | 83 | NA | NA |
| Chlorambucil | 40 | 0 | 65 | NA | NA | |
| UK LRF CLL418 | Fludarabine vs | 176 | 15 | 77 | 31% 3 yr-PFS | NA |
| Chlorambucil | 309 | 8 | 70 | 23% 3 yr-PFS | NA | |
| CAM30727 | Alemtuzumab vs | 149 | 22 | 83 | NA | NA |
| Chlorambucil | 148 | 2 | 55 | NA | NA | |
| Study . | Agent . | No. Pts. . | % CR . | % OR . | RD . | OS (mo) . |
|---|---|---|---|---|---|---|
| Abbreviations: GCLLSG, German CLL Study Group; Pts, patients; CR, complete remission; OR, overall response; RD, remission duration; OS, overall survival; mo, months; NR, not reached; TTP, time-to-progression; NA, not available; UK LRF, UK Leukemia Research Fund | ||||||
| Leporrier et al9 | Fludarabine vs | 341 | 40 | 71 | 32 mo (TTP) | 69 |
| CAP vs | 240 | 15 | 58 | 28 mo (TTP) | 70 | |
| CHOP | 357 | 30 | 72 | 30 mo (TTP) | 67 | |
| Rai et al10 | Fludarabine + | |||||
| Chlorambucil vs | 123 | 20 | 61 | NR | 55 | |
| Fludarabine vs | 170 | 20 | 63 | 25 mo (TTP) | 66 | |
| Chlorambucil | 181 | 4 | 37 | 14 mo (TTP) | 56 | |
| French Coop. Group8 | Fludarabine vs | 52 | 23 | 71 | NR | 60%@4 yr |
| CAP | 48 | 17 | 60 | 7 | 60%@4 yr | |
| GCLLSG-CLL511 | Fludarabine vs | 46 | 11 | 83 | NA | NA |
| Chlorambucil | 40 | 0 | 65 | NA | NA | |
| UK LRF CLL418 | Fludarabine vs | 176 | 15 | 77 | 31% 3 yr-PFS | NA |
| Chlorambucil | 309 | 8 | 70 | 23% 3 yr-PFS | NA | |
| CAM30727 | Alemtuzumab vs | 149 | 22 | 83 | NA | NA |
| Chlorambucil | 148 | 2 | 55 | NA | NA | |